Skip to Content

Targeted Intradermal IL-17

Systemic Bi-Specific IL-17

Pemphigus Vulgaris PC111

Aseptic Processing

cGMP Manufacturing

Process development & scale-up

Analytical Methods Development

Quality and Regulatory Standards

Expert Insights on Drug Development

Scinai BioServices Inc.

Investor Relations

Shareholders Meeting

Knowledge Center

Targeted Intradermal IL-17

Systemic Bi-Specific IL-17

Pemphigus Vulgaris PC111

Aseptic Processing

cGMP Manufacturing

Process development & scale-up

Analytical Methods Development

Quality and Regulatory Standards

Expert Insights on Drug Development

Scinai BioServices Inc.

Investor Relations

Shareholders Meeting

Knowledge Center

Targeted Intradermal IL-17

Systemic Bi-Specific IL-17

Pemphigus Vulgaris PC111

Aseptic Processing

cGMP Manufacturing

Process development & scale-up

Analytical Methods Development

Quality and Regulatory Standards

Expert Insights on Drug Development

Scinai BioServices Inc.

Folder: INVESTORS

Investor Relations

Shareholders Meeting

Folder: RESOURCES

Knowledge Center

Folder: NEWS & EVENTS

Scinai Immunotherapeutics featured in The Marker Labels Biomed Magazine

Mar 3

Written By Amir Reichman

Amir Reichman

biomed wire featuring amir recihman ceo of scinai immunotherapeutics ($scni)

Investors

News and Events

Contact

About Us

Science

CDMO Services

Copyright 2025 Scinai Immunotherapeutics Ltd. All Rights Reserved | Terms of Use | Privacy Policy